DAFNA Capital Management LLC
13F Reported Value
ⓘ$439.6M
Holdings
83
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
DAFNA Capital Management LLC disclosed 83 positions worth $439.6M in its Form 13F-HR for Q1 2026, led by $RVMD (Revolution Medicines, Inc.) at 12.8% of the equity portfolio. During the quarter the fund opened 10 new positions and exited 4 — including a new stake in $FULC. The portfolio is most concentrated in Healthcare (87.5% of disclosed assets). All figures are sourced directly from DAFNA Capital Management LLC’s Form 13F-HR filing with the SEC under CIK 1389933.
AI Fund Analysis
Diversifying
$RVMD
$STXS
$DAWN
$ATRC
$NKTR
$MBX
$INGN
$BCRX
$ARAYSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$56.5M580,678 sh SPDR S&P BIOTECH ETF
—Quality
$40.7M318,505 sh- 16.6#2,732
Quality
$25.2M13,680,554 sh - 42.6
Quality
$21.0M978,463 sh - 47.6
Quality
$17.0M597,431 sh - 10.5
Quality
$15.9M476,740 sh - 12.9
Quality
$14.6M250,772 sh - 28.0
Quality
$14.3M217,497 sh - —
Quality
$13.4M2,418,882 sh - 10.2
Quality
$11.9M165,178 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| Revolution Medicines, Inc.$RVMD | — | $56.5M | 580,678 |
| SPDR S&P BIOTECH ETF | — | $40.7M | 318,505 |
| Stereotaxis, Inc.$STXS | 16.6#2,732 | $25.2M | 13,680,554 |
| Day One Biopharmaceuticals, Inc.$DAWN | 42.6 | $21.0M | 978,463 |
| AtriCure, Inc.$ATRC | 47.6 | $17.0M | 597,431 |
 IDEAYA Biosciences, Inc.$IDYA | 10.5 | $15.9M | 476,740 |
 Xenon Pharmaceuticals Inc.$XENE | 12.9 | $14.6M | 250,772 |
 CYTOKINETICS INC$CYTK | 28.0 | $14.3M | 217,497 |
 COMPASS Pathways plc$CMPS | — | $13.4M | 2,418,882 |
| NEKTAR THERAPEUTICS$NKTR | 10.2 | $11.9M | 165,178 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of DAFNA Capital Management LLC's 83 positions.
Showing top 10 of 83 holdings.
Sector Allocation
Healthcare
$384.5M
Other
$55.1M
Full Holdings — DAFNA Capital Management LLC (Q1 2026)
All 83 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $RVMD | Revolution Medicines, Inc. | $56.5M | 12.8% | -4% | — |
| 2 | — | SPDR S&P BIOTECH ETF | $40.7M | 9.3% | -5% | — |
| 3 | $STXS | Stereotaxis, Inc. | $25.2M | 5.7% | +0% | 16.6 |
| 4 | $DAWN | Day One Biopharmaceuticals, Inc. | $21.0M | 4.8% | -2% | 42.6 |
| 5 | $ATRC | AtriCure, Inc. | $17.0M | 3.9% | +0% | 47.6 |
| 6 | $IDYA | IDEAYA Biosciences, Inc. | $15.9M | 3.6% | -6% | 10.5 |
| 7 | $XENE | Xenon Pharmaceuticals Inc. | $14.6M | 3.3% | -13% | 12.9 |
| 8 | $CYTK | CYTOKINETICS INC | $14.3M | 3.3% | -41% | 28 |
| 9 | $CMPS | COMPASS Pathways plc | $13.4M | 3.0% | +198% | — |
| 10 | $NKTR | NEKTAR THERAPEUTICS | $11.9M | 2.7% | +120% | 10.2 |
| 11 | — | ISHARES NASDAQ BIOTECH INDX | $10.5M | 2.4% | -9% | — |
| 12 |  $RCUS | Arcus Biosciences, Inc. | $9.6M | 2.2% | +3% | 12 |
| 13 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $9.3M | 2.1% | +0% | 75.4 |
| 14 |  $LRMR | Larimar Therapeutics, Inc. | $9.1M | 2.1% | +116% | — |
| 15 |  $BCAX | Bicara Therapeutics Inc. | $8.4M | 1.9% | +61% | — |
| 16 |  $AXGN | Axogen, Inc. | $8.3M | 1.9% | -48% | 38 |
| 17 |  $BHVN | Biohaven Ltd. | $7.2M | 1.6% | -11% | — |
| 18 |  $TNDM | TANDEM DIABETES CARE INC | $6.8M | 1.6% | +0% | 34.8 |
| 19 |  $DNLI | Denali Therapeutics Inc. | $6.1M | 1.4% | +0% | — |
| 20 |  $ASND | Ascendis Pharma A/S | $5.9M | 1.4% | +0% | 41.5 |
| 21 |  $IPSC | Century Therapeutics, Inc. | $5.5M | 1.3% | -13% | 43.5 |
| 22 |  $DXCM | DEXCOM INC | $5.4M | 1.2% | -2% | 77.9 |
| 23 |  $KALV | KalVista Pharmaceuticals, Inc. | $5.4M | 1.2% | -25% | 25.9 |
| 24 | $ASND | Ascendis Pharma A/S | $5.3M | 1.2% | -18% | 41.5 |
| 25 | $MBX | MBX Biosciences, Inc. | $5.2M | 1.2% | +6% | — |
| 26 | $INGN | Inogen Inc | $5.2M | 1.2% | +2% | 35.5 |
| 27 |  $SNDX | Syndax Pharmaceuticals Inc | $5.1M | 1.2% | -22% | 30 |
| 28 |  $ALKS | Alkermes plc. | $4.9M | 1.1% | +7% | — |
| 29 |  $STOK | Stoke Therapeutics, Inc. | $4.3M | 1.0% | +20% | 53.4 |
| 30 | $BCRX | BIOCRYST PHARMACEUTICALS INC | $4.1M | 0.9% | +3% | 37.2 |
| 31 | — | GALAPAGOS NV | $3.9M | 0.9% | +0% | — |
| 32 |  $IMVT | Immunovant, Inc. | $3.7M | 0.8% | +0% | — |
| 33 |  $EWTX | Edgewise Therapeutics, Inc. | $3.5M | 0.8% | -30% | — |
| 34 |  $MPLT | MapLight Therapeutics, Inc. | $3.5M | 0.8% | +19% | — |
| 35 |  $ALLO | Allogene Therapeutics, Inc. | $3.3M | 0.8% | -1% | — |
| 36 |  $PRCT | PROCEPT BioRobotics Corp | $3.0M | 0.7% | +0% | 34.8 |
| 37 |  $ALGN | ALIGN TECHNOLOGY INC | $2.6M | 0.6% | -6% | 58.2 |
| 38 |  $PRQR | ProQR Therapeutics N.V. | $2.5M | 0.6% | +0% | — |
| 39 |  $HELP | CYBIN INC. | $2.4M | 0.5% | +10% | — |
| 40 |  $RAPP | Rapport Therapeutics, Inc. | $2.3M | 0.5% | +0% | — |
| 41 |  $PODD | INSULET CORP | $2.3M | 0.5% | +58% | 70.4 |
| 42 |  $GPCR | Structure Therapeutics Inc. | $2.2M | 0.5% | +26% | — |
| 43 |  $IMTX | Immatics N.V. | $2.2M | 0.5% | -14% | — |
| 44 |  $CLDX | Celldex Therapeutics, Inc. | $2.2M | 0.5% | +0% | 13.2 |
| 45 |  $LXEO | Lexeo Therapeutics, Inc. | $2.2M | 0.5% | +11% | — |
| 46 |  $ALEC | Alector, Inc. | $2.0M | 0.4% | +0% | 8.9 |
| 47 |  $VKTX | Viking Therapeutics, Inc. | $1.9M | 0.4% | +0% | — |
| 48 |  $KURA | Kura Oncology, Inc. | $1.9M | 0.4% | +0% | 9.1 |
| 49 |  $PROF | Profound Medical Corp. | $1.7M | 0.4% | -8% | — |
| 50 |  $FULC | Fulcrum Therapeutics, Inc. | $1.6M | 0.4% | NEW | — |
| 51 |  $AQST | Aquestive Therapeutics, Inc. | $1.5M | 0.3% | -2% | 11.7 |
| 52 |  $MDWD | MediWound Ltd. | $1.5M | 0.3% | -17% | — |
| 53 |  $KIDS | ORTHOPEDIATRICS CORP | $1.5M | 0.3% | NEW | 33.4 |
| 54 |  $RARE | Ultragenyx Pharmaceutical Inc. | $1.3M | 0.3% | +282% | 31 |
| 55 |  $ENGN | enGene Therapeutics Inc. | $1.3M | 0.3% | +14% | — |
| 56 |  $NGNE | Neurogene Inc. | $1.1M | 0.3% | +102% | — |
| 57 |  $SPRY | ARS Pharmaceuticals, Inc. | $1.1M | 0.3% | -27% | 29.7 |
| 58 |  $CTMX | CytomX Therapeutics, Inc. | $1.1M | 0.3% | NEW | 19.1 |
| 59 |  $MAZE | Maze Therapeutics, Inc. | $1.0M | 0.2% | NEW | 19.7 |
| 60 |  $MLYS | Mineralys Therapeutics, Inc. | $1.0M | 0.2% | +0% | — |
| 61 |  $SCYX | SCYNEXIS INC | $996,630 | 0.2% | NEW | — |
| 62 |  $ORIC | Oric Pharmaceuticals, Inc. | $945,460 | 0.2% | -30% | — |
| 63 |  $INSP | Inspire Medical Systems, Inc. | $938,756 | 0.2% | +112% | 46 |
| 64 |  $PYPD | PolyPid Ltd. | $910,602 | 0.2% | +0% | — |
| 65 |  $TELA | TELA Bio, Inc. | $893,438 | 0.2% | +0% | 24.9 |
| 66 |  $ZBIO | Zenas BioPharma, Inc. | $830,875 | 0.2% | NEW | 14.4 |
| 67 |  $VRCA | Verrica Pharmaceuticals Inc. | $813,136 | 0.2% | -11% | 26.1 |
| 68 |  $FATE | FATE THERAPEUTICS INC | $660,000 | 0.1% | +0% | 6.7 |
| 69 |  $ANNX | Annexon, Inc. | $652,678 | 0.1% | -57% | — |
| 70 | $ARAY | ACCURAY INC | $652,205 | 0.1% | +20% | 22.7 |
| 71 |  $NAMS | NewAmsterdam Pharma Co N.V. | $640,200 | 0.1% | NEW | — |
| 72 |  $ACET | Adicet Bio, Inc. | $638,860 | 0.1% | +0% | — |
| 73 |  $BNTX | BioNTech SE | $622,160 | 0.1% | +0% | — |
| 74 |  $PLRX | PLIANT THERAPEUTICS, INC. | $613,620 | 0.1% | NEW | — |
| 75 |  $CGEN | COMPUGEN LTD | $549,078 | 0.1% | -5% | — |
| 76 |  $OBIO | Orchestra BioMed Holdings, Inc. | $539,074 | 0.1% | +0% | 8.7 |
| 77 |  $FHTX | Foghorn Therapeutics Inc. | $534,686 | 0.1% | -12% | 11.2 |
| 78 |  $IBIO | iBio, Inc. | $367,912 | 0.1% | NEW | — |
| 79 |  $BCYC | BICYCLE THERAPEUTICS PLC | $299,243 | 0.1% | +0% | — |
| 80 |  $ADCT | ADC Therapeutics SA | $270,304 | 0.1% | -6% | 16.3 |
| 81 |  $KPTI | Karyopharm Therapeutics Inc. | $255,106 | 0.1% | -10% | 20.4 |
| 82 |  $AUTL | Autolus Therapeutics plc | $247,456 | 0.1% | +0% | — |
| 83 |  $NMRA | Neumora Therapeutics, Inc. | $136,500 | 0.0% | NEW | — |
New Positions (10)
$FULC Fulcrum Therapeutics, Inc.$1.6M$KIDS ORTHOPEDIATRICS CORP$1.5M$CTMX CytomX Therapeutics, Inc.$1.1M$MAZE Maze Therapeutics, Inc.$1.0M$SCYX SCYNEXIS INC$996,630$ZBIO Zenas BioPharma, Inc.$830,875$NAMS NewAmsterdam Pharma Co N.V.$640,200$PLRX PLIANT THERAPEUTICS, INC.$613,620$IBIO iBio, Inc.$367,912$NMRA Neumora Therapeutics, Inc.$136,500
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for DAFNA Capital Management LLC including:
Track DAFNA Capital Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for DAFNA Capital Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: DAFNA Capital Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For DAFNA Capital Management LLC (SEC CIK: 1389933), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in DAFNA Capital Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.